Canadian Authorities Close Probe of Potential Anticompetitive Tactics by Janssen

February 28, 2019

Canada’s Competition Bureau has closed an investigation into potential anticompetitive behavior by Janssen.

The bureau ended its probe into Janssen potentially blocking biosimilars for its drug Remicade (infliximab), saying that while the Johnson & Johnson subsidiary engaged in potentially concerning behavior, there was insufficient evidence it was likely to lesson or prevent competition.

The allegations claimed Janssen supplied Canadian hospitals with Remicade for one cent per vial and provided it for free to uninsured patients while entering into contracts with insurers and providers that required it to prioritize Remicade over biosimilars.

View today's stories